retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces Liver Fat Content by 86% Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

Initial Bioimpedance Spectroscopy Measurements: Weight: 234 lbs Body Fat Percentage: 45.7% BMI: 33.4 Body Fat Mass: 109 lbs Lean Body Mass: 130 lbs Skeletal Muscle Mass: 71 lbs ECW/TBW (Extracellular Water/Total Body Water): 0.401 in both legs Early Breakthroughs Within just three weeks of starting Tirzepatide, JH experienced a remarkable improvement in her mobility

Those numbers are trial averages, not guarantees

No fee unless we win: You only pay legal fees if we successfully secure a settlement or jury award for you

Months 612 and beyond: Weight loss continues but typically at a slower rate as the body reaches a new equilibrium